Press Releases
Back to Previous Page
 


News Release

November 18, 2019
Your Contact:
karen.tiano@milliporesigma.com
Phone: +1 978 495 0093


MilliporeSigma Wins R&D 100 Award for First-to-Market Biopharma Purification Innovation

  • Eshmuno® CP-FT Resin yields 10x higher capacities than traditional methods
  • First cation exchange resin developed for flow-through removal of aggregates using frontal chromatography

Burlington, Massachusetts, November 18, 2019 — MilliporeSigma today announced it has received a prestigious R&D 100 Award for its Eshmuno® CP-FT Resin, a first-to-market product used in biopharmaceutical manufacturing. The R&D 100 Awards honor the 100 most innovative and significant technologies introduced in the past year. MilliporeSigma has received 10 R&D 100 Awards in the past seven years.

“This award recognizes our innovation in research and development for a product that helps biomanufacturers bring new therapies to patients faster and more cost effectively,” said Udit Batra, CEO, MilliporeSigma. “Congratulations to our extended teams, who live our purpose every day by solving the toughest problems in life science in collaboration with the global scientific community.”

Aggregates are impurities in monoclonal antibody drugs that can reduce efficacy and therefore pose significant risk to patients. These impurities are challenging to remove in the purification process of drug manufacturing. MilliporeSigma’s Eshmuno® CP-FT resin is a tool that removes aggregates, delivering capacities 10 times higher than traditional bind/elute chromatography. The significant reduction in resin and buffer volume results in a smaller manufacturing footprint as well as lower costs. The Eshmuno® CP-FT resin is part of MilliporeSigma’s BioContinuum™ Polishing Platform.

The R&D 100 Awards are among the most prestigious innovation awards in the world, honoring research and development pioneers. MilliporeSigma representatives will accept the award at the 57th Annual R&D 100 Awards gala in San Francisco, California on December 5.

Follow MilliporeSigma on Twitter @MilliporeSigma, on Facebook @MilliporeSigma and on LinkedIn.

About the Life Science Business of Merck KGaA, Darmstadt, Germany

The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has some 21,000 employees and 59 manufacturing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services. Udit Batra is the global chief executive officer of MilliporeSigma.

Merck KGaA, Darmstadt, Germany completed its $17 billion acquisition of Sigma-Aldrich in November 2015, creating a leader in the $125 billion global life science industry.

Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. Around 56,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene-editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2018, Merck KGaA, Darmstadt, Germany, generated sales of €14.8 billion in 66 countries.

The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck, KGaA, Darmstadt, Germany, visit www.emdgroup.com.